New chairman at Oxford BioTherapeutics
This article was originally published in Scrip
Oxford BioTherapeutics (UK) has named Dr Michael Moore non-executive chairman. He joins the company after five years at the UK biotechnology firm Piramed, where he served as CEO until its acquisition by Roche in 2008. Before that, Dr Moore was chief scientific officer and research director at Xenova.